On February 6, Cipla announced that its chairman and managing director Yusuf Hamied would step down as managing director, as of March 31, four decades after he assumed the role following the demise of his father and Cipla founder K A Hamied. He will continue as non-executive chairman. In this conversation, Hamied makes known his rarely-expressed views on far-reaching management and strategy changes at the company. Continue reading “The Y K Hamied Interview : Part Three”
As India considers granting more compulsory licences on patented drugs to improve reach and affordability some experts have predicted more voluntary licensing deals – where the innovator voluntarily gives a licence to a generic company to sell its product and hopes to avoid a compulsory licence. Cipla, a leading patent challenger in India, has yet to get one Continue reading “The Y K Hamied Interview : Part Two”
On January 29, Yusuf Khwaja Hamied, 75, chairman of India’s third-largest drug maker Cipla, and the Grand Old Man of the Indian pharmaceuticals industry, sat down with Gauri Kamath at Cipla’s Mumbai headquarters for a wide-rangeing interview. The energetic Hamied was in his element, answering questions patiently and holding forth on a variety of issues untiringly for over an hour.
Apothecurry presents the Y K Hamied interview in three parts. Below is part one. Continue reading “The Y K Hamied Interview : Part One”